Create successful ePaper yourself
Turn your PDF publications into a flip-book with our unique Google optimized e-Paper software.
<strong>IMS</strong> COM PANY PRO FILES NOVARTIS SUBSIDIARY LISTING<br />
Postal Ad dress: PO Box 23510, Dubai<br />
Street Ad dress: Twin Tow ers, Suite Nr.1401,<br />
Beniyas Road, Deira, Dubai<br />
Tel: +971 4 227 8005<br />
Fax: +971 4 223 5369<br />
De scrip tion: Pro moter, sales/detailer. Prod uct<br />
ranges in clude: phar ma ceu ti cal prod ucts<br />
(branded, pre scrip tion), hos pi tal<br />
pharmaceuticals, oph thal mic products.<br />
Phar ma ceu ti cal Sales: US$ 16-18 mil lion<br />
Prod ucts (% of Sales by Lead ing 5): 60-65%<br />
Ther a peu tic Classes (% of Sales by Lead ing<br />
5): 75-80%<br />
Dose Forms (% of Sales by Lead ing 5):<br />
90-95%<br />
Prin ci pal Prod ucts:<br />
VOLTAREN (antirheumatic non-steroidal)<br />
CATAFLAM (antirheumatic non-steroidal)<br />
CO-DIOVAN (an gio ten sin-II an tag o nist com bi na -<br />
tion)<br />
DIOVAN (an gio ten sin-II an tag o nist plain)<br />
LAMISIL NP (antifungal sys temic)<br />
Ther a peu tic Range:<br />
anti rheu ma tics sys temic 42%<br />
renin-an gio ten sin sys tem agents 18%<br />
ophthalmologicals 8%<br />
antifungals sys temic 4%<br />
lipid-reg u lat ing/antiatheroma prep a ra tions 4%<br />
Lead ing Dose Forms:<br />
coated tab lets 44%<br />
tab lets 27%<br />
liq uids 9%<br />
cap sules 7%<br />
am poules 4%<br />
URUGUAY<br />
NOVARTIS<br />
Full Name: Novartis Uru guay S.A.<br />
Street Ad dress: Casilla Correo 605, 11200 Mon -<br />
te vi deo<br />
Tel: +598 2 4133694<br />
Fax: +598 2 4033245<br />
De scrip tion: Man u fac turer, im porter, dis trib u -<br />
tor, pro moter, sales/detailer. Im ports, dis trib utes,<br />
pro motes, sells/de tails for other com pa nies. Prod -<br />
uct ranges in clude: phar ma ceu ti cal prod ucts<br />
(branded, pre scrip tion, non-pre scrip tion), hos pi -<br />
tal pharmaceuticals, di etetic/nu tri tional prod ucts,<br />
bio tech nol ogy prod ucts, oph thal mic products.<br />
Established 1997.<br />
Con tacts (Pharm): Chair man: Cesar Casal;<br />
Com mer cial Op er a tions: Julio Godin; Mar ket Re -<br />
search: Arnoldo Giganda, Luis Ro dri guez<br />
USA<br />
CHIRON<br />
Full Name: Chiron Cor po ra tion<br />
Street Ad dress: 4560 Hor ton Street, Emeryville,<br />
Cal i for nia 94608-2916<br />
Tel: +1 510 655 8730<br />
Fax: +1 510 655 9910<br />
Email: com mu ni ca tions@chiron.com<br />
Home Page: www.chiron.com<br />
De scrip tion: Man u fac turer, re searcher, de vel -<br />
oper. Prod uct ranges in clude: phar ma ceu ti cal<br />
prod ucts (branded, unbranded). Es tab lished<br />
1981.<br />
Con tacts (Pharm): Chair man: Howard Pien,<br />
Sean P. Lance, Dr Jack Goldstein; Com mer cial<br />
Op er a tions: Bryan Walser; Re search & De vel op -<br />
ment: Rino Rappuoli<br />
Par ent of: Chiron Vac cines, UK (100%); Biocine,<br />
USA (di vi sion); Lynx Ther a peu tics, USA (13%);<br />
Ma trix, USA (100%).<br />
CIBA VI SION<br />
Full Name: CIBA Vi sion Cor po ra tion<br />
Street Ad dress: 11460 Johns Creek Park way,<br />
Du luth, Geor gia 30097<br />
Tel: +1 770 476 3937<br />
Fax: +1 770 418 4256<br />
Home Page: www.cibavision.com<br />
De scrip tion: Man u fac turer, re searcher, de vel -<br />
oper, im porter, dis trib u tor, pro moter. Prod uct<br />
ranges in clude: phar ma ceu ti cal prod ucts<br />
(branded, pre scrip tion, non-pre scrip tion), hos pi -<br />
tal pharmaceuticals, di ag nos tic products.<br />
Established 1989.<br />
Sub sid iary of: Novartis, Swit zer land (100%)<br />
Phar ma ceu ti cal Sales: US$ 65-70 mil lion<br />
Prod ucts (% of Sales by Lead ing 5): 90-95%<br />
Ther a peu tic Classes (% of Sales by Lead ing<br />
5): n.a.<br />
Dose Forms (% of Sales by Lead ing 5):<br />
95-100%<br />
Prin ci pal Prod ucts:<br />
VISUDYNE (oc u lar antineovascularization prod -<br />
uct)<br />
AOSEPT CLEAR CARE (con tact lens prep a ra tion)<br />
AQUIFY MPS (con tact lens prep a ra tion)<br />
LENSEPT (con tact lens prep a ra tion)<br />
© 2009 <strong>IMS</strong> Health In cor po rated or its af fil i ates Page 220